ArticleiScience2026
Oxygen-stable streptolysin O variant enables mitochondrial ATP synthesis analysis in minimal cells blood and tissues.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantifying mitochondrial ATP synthesis remains inaccessible in rare cells, blood, and microdissected tissues because of the biochemical instability of streptolysin O (SLO)-based permeabilization. Here, we introduce an oxygen-stable SLO variant, streptolysin O tolerant (SLOT), and an improved mitochondrial ATP synthesis capacity (iMASC) assay to enable sensitive analysis across diverse samples. SLOT combines non-essential N-terminal deletion (Δ1-77) with a C530A substitution, conferring reductant-independent activity and long-term stability. Temperature-controlled activation restricts permeabilization to the plasma membrane, preserving mitochondrial function. iMASC assay supports continuous measurement for more than 1 h from 10 to 20 cells and applies to adherent and suspension cells, whole blood, and microdissected tissues. Using this platform, we identify platelets as dominant contributors to glycerol-3-phosphate-driven ATP synthesis in murine blood and enable sequential dissection of respiratory chain and ATP synthase activities within single tissues. This framework establishes a broadly applicable approach for mitochondrial metabolism analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.